A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (BALL) Including a Stratum Evaluating Dasatinib (IND# 73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
This randomized phase III trial studies how well combination chemotherapy works in treating
young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come
back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase
inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and
giving the drugs in different doses and in different combinations may kill more cancer cells.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.